低強度のエストロゲンと子宮内膜がんのリスク:ケース・コントロール研究
E Weiderpass1, J A Baron, H O Adami
1Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden. Elisabete.Weiderpass@mep.ki.se
Lancet (London, England)
|June 8, 1999
まとめ
口服による低効能エストロゲン製剤,特にエストリオールは,閉経後の女性の子宮内膜がんリスクを大幅に増加させる. 陰道での使用は最小限の関連を示し,注意深いモニタリングとプロゲスタゲン考慮の必要性を強調しました.
科学分野:
- 婦人科腫瘍学 婦人科腫瘍学
- エンドクリノロジー エンドクリノロジー
- 生殖器保健は,生殖器の健康についてです.
背景:
- 排尿器系症状は閉経後の女性に多く見られ,しばしば低効力エストロゲンで治療されます.
- これらの製剤の子宮内膜安全性,特に腫瘍形成のリスクに関して,まだ完全に理解されていません.
研究 の 目的:
- 低効能エストロゲン製剤と,閉経後の女性の子宮内膜腫瘍のリスクとの関連を調査する.
主な方法:
- スウェーデンの全国の人口を対象とした症例対照研究.
- 789人の子宮内膜がん患者と3368人の対照群を対象とした.
- 確率比率の計算のために無条件のロジスティック回帰を用いた. histopathological レビューと多変量調整後に.
主要な成果:
- 5年以上の経口エストリオール (1〜2mg/日) の使用は,子宮内膜がん (OR 3.0) と非典型性多発症 (OR 8.3) の相対リスクの増加と関連していました.
- このリスクは,明確に区別されたがんでは高かったが,治療を中止した後に急速に減少した.
- ヴァギナルの低効能エストロゲンは,子宮内膜腫瘍のリスクと弱い関連しか示さなかった.
結論:
- 経口による低効能エストロゲン製剤は,陰道製剤とは異なり,子宮内膜腫瘍のリスクが高くなります.
- 口服用製剤を使用している女性には,患者の緊密な監視とプロゲスタゲン添加の検討が推奨されます.
関連する概念動画
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...